PCVX Vaxcyte, Inc.
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances) · Market cap $8.4B · $56.48 on 2026-10-02
No StickerTier CFiscal-year data · FY2025
Price moves
1 week0%
1 month-8%
3 months-3%
6 months-3%
YTD23%
1 year32%
Off 52w high-13%
52w range$40–$65
Price history
Show year-end values
| Year | Price |
|---|---|
| 2020 | $26.57 |
| 2021 | $23.79 |
| 2022 | $47.95 |
| 2023 | $62.80 |
| 2024 | $81.86 |
| 2025 | $46.14 |
| 2026-10-02 (latest) | $56.48 |
Valuation
| Buy (MOS) 50% of Sticker | – | – |
|---|---|---|
| Ten Cap 10× owner earnings − net debt | – | – |
| Payback Time 8-year FCF payback | – | – |
| Sticker Rule #1 intrinsic value | – | – |
| Methods agree price under how many of Ten Cap, Payback, MOS | 0 of 3 | |
| Windage growth g | 11.0% | |
| P/E · 10y median | – | – |
| EPS FY2025 | $-5.63 | |
| FCF yield | -8.0% | |
| Dividend (TTM) · yield | – | – |
| Total return per year, dividends reinvested · 5y · 10y | 17.1% | – |
| Revenue · net income last FY | – | $-1M |
Big Five 1/9 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | -23% | -24% | -27% |
| Sales growth | – | – | – |
| EPS growth | – | – | – |
| BVPS growth | – | 11% | -27% |
| OCF growth | – | – | – |
| Debt payoff (yrs of FCF) | 0.0 |
Events
Event scan (8-Ks, insider buys, 13Ds) runs for stocks that pass the quality screen.